Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 33 of 39, showing 5 Applications out of 193 total, starting on record 161, ending on 165

# Protocol No Study Title Investigator(s) & Site(s)

161.

ECCT/24/02/09   pionERA
    This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of   giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor   (palbociclib, ribociclib or abemaciclib), in participants with estrogen receptor-positive (ER+), human epidermal   growth factor receptor 2-negative (HER2-) advanced breast cancer who have developed resistance to adjuvant   endocrine therapy.   
Principal Investigator(s)
1. Dr Sitna Ali
Site(s) in Kenya
University of Nairobi -Institute of Tropical and Infectious Diseases
 
View

162.

ECCT/24/09/01   L9LS-PD
    Single-use antimalarial monoclonal antibodies for post-discharge malaria prevention in children with severe anaemia or severe malaria in Kenya: A multi-centre, parallel-group, two-arm randomised placebo-controlled non-inferiority trial (L9LS-pd)   
Principal Investigator(s)
1. Mary Iwaret Otiti
Site(s) in Kenya
1. Homa Bay County Teaching and Referral Hospital (Homa Bay county)
2. Siaya County Referral Hospital (Siaya county)
 
View

163.

ECCT/24/03/02   PEARL RSVt Vaccine Study
    Phase III, randomized, observer-blind, placebo-controlled, multi-center, multinational study to evaluate the efficacy, immunogenicity, and safety of a Respiratory Syncytial Virus vaccine in infants and toddlers (PEARL   
Principal Investigator(s)
1. Dr. Janet Nyawira Oyieko
Site(s) in Kenya
1. KEMRI CCR – Butere Clinical Research Centre (Kakamega county)
 
View

164.

ECCT/24/04/02   PEARL RSVt Vaccine Study
    Phase III, randomized, observer-blind, placebo-controlled, multi-center, multinational study to evaluate the efficacy, immunogenicity, and safety of a Respiratory Syncytial Virus vaccine in infants and toddlers (PEARL   
Principal Investigator(s)
1. Dr Fredrick Kipyego Sawe
Site(s) in Kenya
1. Walter Reed Army Institute of Research -Kericho Site (Kericho county)
 
View

165.

ECCT/24/05/05   PEARL RSVt Vaccine Study
    Phase III, randomized, observer-blind, placebo-controlled, multi-center, multinational study to evaluate the efficacy, immunogenicity, and safety of a Respiratory Syncytial Virus vaccine in infants and toddlers (PEARL   
Principal Investigator(s)
1. Dr Kariuki Simon Kariuki
2. Patricia Odero Ojwang
Site(s) in Kenya
1. Kenya Medical Research Institute-Dr Kariuki (Kisumu county)
 
View